CME/CE PODCAST: Recognizing the Burden of Residual Symptoms in MDD

The NACE Clinical Highlights Show

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/recognizing-the-burden-of-residual-symptoms-in-mdd-9526
Summary
Early and effective treatment of major depressive disorder (MDD) is essential to prevent persistent residual symptoms, which are associated with worse outcomes. Evidence indicates that residual symptoms, such as impaired cognition, are underrecognized and undertreated in routine clinical care. Recognizing residual symptoms and the factors contributing to suboptimal treatment response is a critical first step to modifying management, with the goal of eliminating residual symptoms and achieving full remission.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss common residual symptoms and other signs of suboptimal treatment response, including the impact of antidepressant side effects and the efficacy of antidepressants for residual symptoms.

This podcast/webcast was recorded and is being used with permission of the presenters.
This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [e-mail].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.